Who is sponsoring NCT01333124?

NCT01333124 is sponsored by National Cancer Center, Korea.

What drugs are being tested in NCT01333124?

Interventions in NCT01333124: chemoradiotherapy with Gemcitabine, Radiation: chemoradiotherapy with Gemcitabine.

What condition does NCT01333124 study?

NCT01333124 studies Resectable Pancreatic Carcinoma.

Is NCT01333124 still recruiting?

NCT01333124 is currently terminated. Last updated 6 April 2020.

Last reviewed 2020-04-06 · How we verify

NCT01333124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma

Terminated Phase 2 Last updated 6 April 2020

What this trial tests

Phase 2 trial testing chemoradiotherapy with Gemcitabine in Resectable Pancreatic Carcinoma in 23 participants. Terminated before completion.

Timeline

28 September 2011

Primary endpoint
31 December 2017

31 December 2017

Quick facts

Lead sponsor	National Cancer Center, Korea
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	28 September 2011
Primary completion	31 December 2017
Estimated completion	31 December 2017
Sites	1 location across South Korea

Drugs / interventions tested

chemoradiotherapy with Gemcitabine
Radiation: chemoradiotherapy with Gemcitabine

Conditions studied

Resectable Pancreatic Carcinoma — all drugs for Resectable Pancreatic Carcinoma →

Sponsor

National Cancer Center, Korea

Who can join

Adults 18 to 70, any sex, with Resectable Pancreatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II study is to evaluate the efficacy of preoperative chemoradiotherapy with gemcitabine (400mg/m2, weekly) for resectable pancreatic cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. · · 2020 · cited 67× · PMID 32083002 · DOI 10.3389/fonc.2020.00041
Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
Seufferlein T, Ettrich TJ. · · 2019 · cited 35× · PMID 30976724 · DOI 10.21037/tgh.2019.03.05
Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients.
van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, et al · · 2019 · cited 24× · PMID 30650521 · DOI 10.3390/cancers11010093
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment.
Yoon KA, Woo SM, Kim YH, Kong SY, et al · · 2019 · cited 18× · PMID 30970447 · DOI 10.5009/gnl18355

Verify or expand the search:

Other recruiting trials for Resectable Pancreatic Carcinoma

Currently open trials in the same condition.

NCT04858334 — APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patient · Phase 2 · recruiting
NCT04560712 — Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery · NA · active not recruiting
NCT03823144 — Intravital Microscopy in Human Solid Tumors · NA · recruiting

Other National Cancer Center, Korea trials

Trials by the same sponsor.

NCT07399561 — Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy · NA · not yet recruiting
NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01333124 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
Last refreshed: 6 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01333124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing